NASDAQ:ADIL - Adial Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 114.13 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.67
▲ +0.28 (6.38%)

This chart shows the closing price for ADIL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adial Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADIL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADIL

Analyst Price Target is $10.00
▲ +114.13% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Adial Pharmaceuticals in the last 3 months. The average price target is $10.00, with a high forecast of $15.00 and a low forecast of $5.00. The average price target represents a 114.13% upside from the last price of $4.67.

This chart shows the closing price for ADIL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Adial Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/26/2021Litchfield Hills ResearchBoost Price TargetBuy$5.00 ➝ $15.00High
8/20/2021Maxim GroupReiterated RatingBuy$5.00Medium
6/29/2021Litchfield Hills ResearchInitiated CoverageBuy$5.00Low
6/7/2019Maxim GroupSet Price TargetBuy$5.00Medium
4/12/2019Dawson JamesReiterated RatingBuyMedium
3/26/2019Maxim GroupSet Price TargetBuy$5.00Low
12/13/2018Maxim GroupReiterated RatingBuy$5.00High
11/14/2018Maxim GroupReiterated RatingBuy$5.00Low
10/30/2018Maxim GroupInitiated CoverageBuy ➝ Buy$5.00Low
10/11/2018Dawson JamesInitiated CoverageBuyHigh
10/1/2018Dawson JamesReiterated RatingBuyLow
(Data available from 9/24/2016 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/26/2021
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2021

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Adial Pharmaceuticals logo
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.
Read More

Today's Range

Now: $4.67
Low: $4.30
High: $4.74

50 Day Range

MA: $3.40
Low: $2.31
High: $4.67

52 Week Range

Now: $4.67
Low: $1.14
High: $4.78

Volume

1,023,178 shs

Average Volume

513,959 shs

Market Capitalization

$94.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Adial Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Adial Pharmaceuticals in the last twelve months: Litchfield Hills Research, and Maxim Group.
View the latest analyst ratings for ADIL.

What is the current price target for Adial Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Adial Pharmaceuticals in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 114.1%. Litchfield Hills Research has the highest price target set, predicting ADIL will reach $15.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $5.00 for Adial Pharmaceuticals in the next year.
View the latest price targets for ADIL.

What is the current consensus analyst rating for Adial Pharmaceuticals?

Adial Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADIL will outperform the market and that investors should add to their positions of Adial Pharmaceuticals.
View the latest ratings for ADIL.

How do I contact Adial Pharmaceuticals' investor relations team?

Adial Pharmaceuticals' physical mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The company's listed phone number is (434) 422-9800 and its investor relations email address is [email protected] The official website for Adial Pharmaceuticals is www.adialpharma.com.